



Scholars Research Library

Der Pharma Chemica, 2011, 3 (6):124-129
(<http://derpharmachemica.com/archive.html>)



ISSN 0975-413X
CODEN (USA): PCHHAX

Synthesis and biological activity of novel phthalamide containing azitidinone

Gunvantsinh T. Desai, F. B. Bux¹ and Arun Singh*²

¹Department of Chemistry, Govt. Geetanjali Girls P.G. College, Bhopal, M.P. India

²Rajya Siksha Kendra, Pustak Bhawan Bhopal, M.P., India

ABSTRACT

4-(1,3-dioxisoindolin-2-yl)benzohydrazide (**1**) undergoes facile condensation with aromatic aldehydes to afford the corresponding N'-arylidene-4-(1,3-dioxisoindolin-2-yl)benzohydrazide (**2a-e**) in good yields. Cyclocondensation of compounds (**2a-e**) with chloro acetyl chloride yields N-(3-chloro-2-oxo-4-arylazetidino-1-yl)-4-(1,3-dioxisoindolin-2-yl)benzamide (**3a-e**). The structures of these compounds were established on the basis of analytical and spectral data. The newly synthesized compounds were evaluated for their antibacterial and antifungal activities.

Keywords: 4-(1,3-dioxisoindolin-2-yl)benzohydrazide, azetidinone, Antibacterial activity.


INTRODUCTION

Heterocyclised products based on hydrazides display diverse biological activities including antibacterial, antifungicidal, analgesic, anti-inflammatory properties [1-18]. These heterocyclic systems find wide use in medicine, agriculture and industry. One of the hydrazides, 2-(1,3-dioxisoindolin-2-yl)acetohydrazide and their condensed products play a vital role in medicinal chemistry [16-18]. A large number of azetidinones containing β -lactam rings [19-22] are known to exhibit various biological activities like antibacterial, antifungal [23] and antibiotic [24] activities. More particularly and recently these types of compounds have been found in the treatment of T.B. and other chemotherapeutic diseases. Hence, it was thought of interest in merging of both azetidinone and phthalamide moieties may enhance the drug activity of compounds up to some extent or might possess some of the above mentioned biological activities. From this point of view, the objective of the present work is to prepare new derivatives of phthalamide containing an azetidinone moiety. Hence the present communication comprises the synthesis of N-(3-chloro-2-aryl-4-oxoazetidino-1-yl)-2-(1,3-dioxisoindolin-2-yl)acetamide (**3a-e**). The research work is scanned in scheme-I.

MATERIALS AND METHODS

Experimental

Melting points were determined in open capillary tubes and were uncorrected. The IR spectra were recorded in KBr pellets on a Nicolet 400D spectrometer and ^1H NMR and ^{13}C NMR spectra were recorded in DMSO with TMS as internal standard on a Bruker spectrometer at 400 MHz and 100 MHz, respectively. LC-MS of selected samples taken on LC-MSD-Trap-SL_01046.



Where R = (a) C₆H₅, (b) 4-OH-C₆H₄, (c) 2-OH-C₆H₄,

(d) 4-OCH₃-C₆H₄, (e) 4-OH-3-OCH₃-C₆H₃,

Preparation of *N'*-arylidene-4-(1,3-dioxoisindolin-2-yl)benzohydrazide (2a-e)**General procedure**

An equimolecular mixture of 4-(1,3-dioxoisindolin-2-yl)benzohydrazide (**1**), (0.01 mole) and the aromatic aldehydes (**a-e**) in ethanol (20 mL) was refluxed on a water bath for 1.5-2.0 hrs. The solid separated was collected by filtration, dried and recrystallized from ethanol. The yields, melting points and other characterization data of these compounds are given in Table -1 & 2.

Table: 1 Analytical Data and elemental analysis of compounds (2a-e)

Compd.	Molecular formula	Yield	M.P. °C	Elemental Analysis					
				%C		%H		%N	
				Found	Calcd.	Found	Calcd.	Found	Calcd.
2a	C ₂₂ H ₁₅ N ₃ O ₃ (369)	84	230	71.5	71.54	4.0	4.09	11.3	11.38
2b	C ₂₃ H ₁₇ N ₃ O ₄ (399)	79	239	69.1	69.17	4.2	4.29	10.5	10.52
2c	C ₂₂ H ₁₅ N ₃ O ₄ (385)	78	238	68.5	68.57	3.9	3.92	10.8	10.90
2d	C ₂₂ H ₁₅ N ₃ O ₄ (385)	82	234	68.5	68.57	3.9	3.92	10.8	10.90
2e	C ₂₃ H ₁₇ N ₃ O ₅ (415)	77	237	66.5	66.50	4.1	4.12	9.9	10.12

Table: 2 Spectral data of compounds (2a-e)

Compd.	Ar-H	-CONH	-N=CH	-CH ₃	-OCH ₃	-OH
2a	7.3-8.1 (m, 13H)	11.80(s)	8.4(s)	-	-	-
2b	7.3-8.1(m, 12H)	11.80(s)	8.4(s)	-	3.9(s)	-
2c	7.3-8.1 (m, 12H)	11.80(s)	8.4(s)	-	-	11.20(s)
2d	7.3-8.1 (m, 12H)	11.80(s)	8.8(s)	-	-	11.20(s)
2e	7.3-8.1 (m, 11H)	11.80(s)	8.4(s)	2.4(s)	-	-

Preparation of *N*-(3-chloro-2-oxo-4-arylazetid-1-yl)-4-(1,3-dioxoisindolin-2-yl) benzamide (3a-e)**General procedure**

A mixture *N'*-arylidene-4-(1,3-dioxoisindolin-2-yl)benzohydrazide (**2a-e**) (0.002 mole) and triethyl amine (TEA) (0.004 mole) was dissolved in 1,4-dioxane (50 ml), cooled, and stirred. To this well-stirred cooled solution chloro acetyl chloride (0.004 mole) was added drop wise within a period of 30 minutes. The reaction mixture was then stirred for an additional 3 hours and left at room temperature for 48 hours. The resultant mixture was concentrated, cooled, poured into ice-cold water, and then air-dried. The product thus obtained was purified by column chromatography over silica gel using 30% ethyl acetate: 70% benzene as eluent. Recrystallization from ether/n-hexane gave white powdered of *N*-(3-chloro-2-oxo-4-arylazetid-1-yl)-4-(1,3-dioxoisindolin-2-yl)benzamide (**3a-e**), which was obtained in 57-76% yield. All the compounds were characterized by analytical and spectral data (Table-3 & 4) of the compounds is assigned in scheme-I.

Table: 3 Analytical data and elemental analysis of Compounds (3a-e)

Compd.	Molecular formula (Mol. wt.)	Yield	M.P. °C	Elemental Analysis					
				%C		%H		%N	
				Found	Calcd.	Found	Calcd.	Found	Calcd.
3a	C ₂₄ H ₁₆ ClN ₃ O ₄ (445)	62	232	64.6	64.65	3.6	3.62	9.4	9.42
3b	C ₂₅ H ₁₈ ClN ₃ O ₅ (475)	63	241	62.9	63.10	3.8	3.81	8.8	8.83
3c	C ₂₄ H ₁₆ ClN ₃ O ₅ (461)	60	239	62.4	62.41	3.4	3.49	8.9	9.10
3d	C ₂₄ H ₁₆ ClN ₃ O ₅ (461)	59	238	62.4	62.41	3.4	3.49	8.9	9.10
3e	C ₂₅ H ₁₈ ClN ₃ O ₆ (491)	54	243	61.0	61.04	3.6	3.69	8.5	8.54

Table: 4 Spectral data of compounds (3a-e)

Compd.	C ₂ -H	C ₃ -H	Ar-H	-CH ₃	-OCH ₃	-OH	-CONH
3a	5.1 (d, 1H)	5.6 (d, 1H)	7.3-8.1 (m, 13H)	-	-	-	7.8(s)
3b	5.1 (d, 1H)	5.6 (d, 1H)	7.3-8.1 (m, 13H)	-	3.9(s)	-	7.8(s)
3c	5.1 (d, 1H)	5.6 (d, 1H)	7.3-8.1 (m, 13H)	-	-	11.20(s)	7.8(s)
3d	5.1 (d, 1H)	5.6 (d, 1H)	7.3-8.1 (m, 13H)	-	-	11.20(s)	7.8(s)
3e	5.1 (d, 1H)	5.6 (d, 1H)	7.3-8.1 (m, 13H)	2.4(s)	-	-	7.8(s)

RESULTS AND DISCUSSION

It was observed that 4-(1,3-dioxoisindolin-2-yl)benzohydrazide (**1**) on condensation with aromatic aldehydes to yield N'-arylidene-4-(1,3-dioxoisindolin-2-yl)benzohydrazide (**2a-e**). The structures of (**2a-e**) were confirmed by elemental analysis and IR spectra showing absorption band at 1628-1645(C=N), 3020-3080 cm⁻¹ (C-H, of Ar.), 1720-1750 cm⁻¹ (-CO), 2815-2850 cm⁻¹ (-OCH₃), 3450-3485 cm⁻¹ (-OH), 2950, 1370 cm⁻¹ (-CH₃). The C, H, N analysis and ¹H NMR data of all compounds are presented in Table -1 & 2.

The cyclocondensation of (**2a-e**) with chloroacetylchloride resulted in formation of N-(3-chloro-2-oxo-4-arylazetidino-1-yl)-4-(1,3-dioxoisindolin-2-yl) benzamide (**3a-e**). The structures assigned to (**3a-e**) were supported by the elemental analysis and IR spectra showing absorption bands at 1750-1760 (C=O of monocyclic β-lactam), 3035-3090 cm⁻¹ (C-H, of Ar.), 3450-3550 cm⁻¹ (-OH), 2820-2850 cm⁻¹ (-OCH₃), 2950, 1370 cm⁻¹ (-CH₃). The C, H, N analysis and ¹H-NMR data of all compounds are presented in Table -3 & 4

The examination of data reveals that the elemental contents are consistent with the predicted structure shown in scheme-I. The IR data also direct for assignment of the predicted structure. The final structure of all compounds is confirmed by LC-MS data of selected samples. The LC-MS of sample **3b** give the molecular ion peak (m/z) at 492. These values correspond to their molecular weight.

BIOLOGICAL SCREENING

Table: 5 Antibacterial Activities of Compounds (3a-e)

Compounds	Gram +Ve		Gram -Ve	
	<i>Bacillus subtilis</i>	<i>E. coli</i>	<i>Klebsiella promi</i> <i>promi</i>	<i>Staphylococcus aureus</i>
3a	59	69	55	64
3b	65	58	66	66
3c	73	72	57	69
3d	63	64	64	58
3e	54	69	68	59
Tetracycline	79	78	86	67

Antibacterial Activities

Antibacterial activities of all the compounds were studied against gram-positive bacteria (*Staphylococcus aureus* and *Bacillus subtilis*) and gram-negative bacteria (*E. coli*, and *klebsiella promi*
promi) at a concentration of 50 μg/ml by agar cup plate method. Methanol system was used as control in this method. Under similar condition using tetracycline as a standard for comparison carried out control experiment. The area of inhibition of zone measured in mm. Compound 3c

was found more active against the above microbes. Other compounds found to be less or moderate active than tetracycline (Table -5).

Antifungal Activities

The fungicidal activity of all the compounds was studied at 1000 ppm concentration in vitro. Plant pathogenic organisms used were *rhizopus nigricum*, *aspergillus niger*, *fusarium oxyporium* and *botrydepladia thiobromine*. The antifungal activity of all the compounds (3a-e) was measured on each of these plant pathogenic strains on a potato dextrose agar (PDA) medium. Such a PDA medium contained potato 200gm, dextrose 20gm, agar 20gm and water one liter. Five days old cultures were employed. The compounds to be tested were suspended (1000ppm) in a PDA medium and autoclaved at 120° C for 15 min. at 15atm.pressure. These medium were poured into sterile Petri plates and the organisms were inoculated after cooling the Petri plates. The percentage inhibition for fungi was calculated after five days using the formula given below:

$$\text{Percentage of inhibition} = 100(X-Y) / X$$

Where, X = Area of colony in control plate
Y = Area of colony in test plate

The fungicidal activity displayed by various compounds (3a-e) is shown in Table-6.

Table: 6 Antifungal Activities of Compounds (3a-e)

Compounds	Zone of Inhibition at 1000 ppm (%)			
	<i>Rhizopus Nigricum</i>	<i>Aspergillus niger</i>	<i>Fusarium oxyporium</i>	<i>Botrydepladia Thiobromine</i>
3a	56	65	73	65
3b	69	60	70	67
3c	65	64	73	70
3d	76	49	68	66
3e	73	68	64	68

REFERENCES

- [1] R. Kalsi, M. Shrimali, T. N. Bhalla, J. P. Barthwal, *Indian J. Pharm. Sci.* **2006**, 41, 353.
- [2] Y. Janin, *Bioorg. Med. Chem.* **2007**, 15, 2479.
- [3] E. Gursoy, N. Guzeldemirci-Ulusoy, *Eur. J. Med. Chem.* **2007**, 42, 320.
- [4] M. R. Rao, K. Hart, N. Devanna and K. B. Chandrasekhar, *Asian J. Chem.* **2008**, 20, 1402.
- [5] K. B. Kaymakcioglu, E. E. Oruc, S. Unsalan, F. Kandemirli, N. Shvets, S. Rollas, D. Anatholy, *Eur. J. Med. Chem.* **2006**, 41, 1253.
- [6] M. R. Shiradkar, K. K. Murahari, H. R. Gangadasu, T. Suresh, C. C. Kalyan, D. Panchal, R. Kaur, P. Burange, J. Ghogare, V. Mokale, M. Raut, *Bioorg. Med. Chem.*, **2007**, 15, 3997.
- [7] S. Gemma, G. Kukreja, C. Fattorusso, M. Persico, M. Romano, M. Altarelli, L. Savini, G. Campiani, E. Fattorusso, N. Basilico, *Bioorg. Med. Chem. Lett.* **2006**, 16, 5384.
- [8] D. Sriram, P. Yogeewari, K. Madhu, *Bioorg. Med. Chem. Lett.* **2006**, 15, 4502.
- [9] A. Nayyar, R. Jain, *Curr. Med. Chem.* **2006**, 12, 1873.
- [10] R. M. Fikry, N. A. Ismael, A. A. El-Bahnasawy, A. A. Sayed El-Ahl., *Phosphorus Sulfur and Silicon.* **2006**, 179, 1227.
- [11] A. Walcourt, M. Loyevsky, D. B. Lovejoy, V. R. Gordeuk, D. R. Richardson, *Int. J. Biochem. Cell Biol.* **2004**, 36, 401 .

- [12] M. G. Mamolo, V. Falagiani, D. Zampieri, L. Vio, E. Banfi , G. Scialino, *Farmaco* **2003**, 58, 631.
- [13] N. Terzioglu, A. Gursoy, *Eur. J. Med. Chem.*, **2003**, 38, 781.
- [14] S. G. Kucukguzel, E. E. Oruc, S. Rollas, F. Sahin, A. Ozbek, *Eur. J. Med. Chem.* **2002**, 37, 197.
- [15] S. Rollas, N. Gulerman, H. Erdeniz, *Farmaco*, **2002**, 57, 171.
- [16] Al- Mawsawi LQ, R. Dayam, L. Taheri, M. Witvrouw, Z. Debyser, N. Neamati, *Bioorg. Med. Chem. Lett.* **2007**, 17(23) 6472.
- [17] C. Plasencia, R. Daym, Q. Wang, J. Pinski, T. R. Jr. Burke, D. I. Quinn, and N. Neamati, *Mol. Cancer Ther.* **2005**, 4(7) 1105.
- [18] H. Zhao, N. Neamati, S. Sunder, H. Hong, S. wang; G. W. Milne, Y. Pommier, T. R. Jr. . Burke, *J. Med. Chem.* **1997**, 40(6) 937.
- [19] H. S. Patel, H. J. Mistry, H. D. Desai, *Oriental J. chem.* **2003**, 19(1), 187-192.
- [20] H. S. Patel, H. J. Mistry, *Phosphorous, Sulfur and Silicon*, **2004**, 179, 1085-1093.
- [21] K. R. Desai, Bhanvesh Naik, *Ind. J. chem.*, **2006**, 45(B), 267-271.
- [22] H. S. Patel, V. K. Patel, *Ind. J. heterocyclic chem.*, **2003**, 12, 253-256.
- [23] V. V. Mulwad, B. P. Choudhari, *Indian J. heterocyclic chem.*, **2003**, 12, 197-200.
- [24] K. Akiba, M. Wada, *Chem. Abstr.*, **1989**, 111, 96964b.